According ALK, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved use of a 1 mg dose of EURneffy adrenaline nasal spray for the treatment of anaphylaxis in children aged 4 and older who weigh 15 kg to 30 kg. The MHRA had previously approved a 2 mg dose of EURneffy for use in adults and children who weigh more than 30 kg in 2025.
The UK approval of the 1 mg dose follows the recent approval of EURneffy 1 mg for the same indication in Europe and the FDA’s removal of age restrictions for the 1 mg dose of neffy epinephrine nasal spray. ALK-Abelló acquired the rights to market the nasal spray in the UK and other markets from ARS Pharmaceuticals in 2024.
ALK Executive VP Commercial Operations Europe Flora Beiche-Scholz commented, “This approval reflects our continued commitment to expanding treatment options for children with severe allergies. For decades, children at risk of anaphylaxis have been limited to injectable adrenaline yet fear of needles, hesitancy to act, and incorrect administration mean adrenaline is too often not carried or used in time. EURneffy 1 mg aims to address these barriers, offering a needle-free adrenaline solution with the potential to transform the lives of those living with, or caring for, children with severe allergies. This approval brings us closer to ensuring every family affected by severe allergies has a treatment they will actually carry and use.”
Read the ALK Abello press release
